<DOC>
	<DOC>NCT01429818</DOC>
	<brief_summary>The Purpose of this study was to evaluate the effect of the combination glimepiride/metformin over endothelial dysfunction (ED) in asymptomatic patients with type 2 diabetes mellitus (DM) using 13N-ammonia-positron emission tomography (PET).</brief_summary>
	<brief_title>Endothelial Disfunction Treatment With Glimepiride/Metformin Combination (Glimetal) in Type 2 Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Both genders At least 18 years old Type 2 diabetes mellitus diagnosis Signed Informed Consent History of smoking, hypertension, dyslipidemia, ischemic heart disease or autoimmune rheumatic diseases Pregnancy or lactation History of abuse and/or substance dependence within 6 months preceding the survey. History of glimepiride or metformin allergy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Endothelial dysfunction</keyword>
	<keyword>Diabetes mellitus</keyword>
	<keyword>glimepiride</keyword>
	<keyword>metformin</keyword>
</DOC>